These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27186942)

  • 21. Optimizing the diagnosis and the treatment of iron overload diseases.
    Brissot P
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):359-70. PubMed ID: 26561304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
    Shander A; Cappellini MD; Goodnough LT
    Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.
    Di Maggio R; Maggio A
    Br J Haematol; 2017 Sep; 178(5):676-688. PubMed ID: 28439891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron overload in β-thalassemia intermedia: an emerging concern.
    Musallam KM; Cappellini MD; Taher AT
    Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
    Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
    Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Malcovati L
    Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing prevalence of thalassemia in America: Implications for primary care.
    Sayani FA; Kwiatkowski JL
    Ann Med; 2015; 47(7):592-604. PubMed ID: 26541064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
    Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
    Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiomyopathy in Thalassemia: Quick Review from Cellular Aspects to Diagnosis and Current Treatments.
    Ghanavat M; Haybar H; Pezeshki SMS; Shahjahani M; Jodat H; Elyasi M; Saki N
    Lab Med; 2020 Mar; 51(2):143-150. PubMed ID: 32155272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.